Response and Nippon Kayaku to develop PSA (prostate specific antigen) test:
This article was originally published in Clinica
Executive Summary
Response Biomedical and Japanese company Nippon Kayaku are to collaborate on developing a prostate cancer test for use on Response's quantitative, point-of-care RAMP diagnostic system. The Vancouver, British Columbia company has signed an agreement with the Japanese partner, based in Tokyo, to make a test for the prostate cancer marker prostate specific antigen (PSA). Nippon Kayaku will fund the development and Japanese regulatory submission of the PSA test and will have sales and distribution rights for the product in Japan. Response reserves rights for other markets. The company has already developed a number of tests for other medical conditions for use on the RAMP assay.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.